Allylix secures $6 mil. in venture capital
This article was originally published in The Rose Sheet
Executive Summary
San Diego, Calif.-based biotech firm has raised $6 mil. in Series C financing to commercialize grapefruit-derived nootkatone and other products for food and fragrance applications. Funding validates Allylix's technology platform - which "enables low-cost production of high-value terpene products through yeast fermentation" - and commercial viability, says CEO Carolyn Fritz. Nootkatone is currently produced through grapefruit peel extractions, creating a "long-lasting" citrus flavor used in fruit juices and sodas. Allylix plans to implement a more cost-efficient production process and expand applications of nootkatone to a broader range of products, including fragrances and pharmaceuticals, according to its Web site. Allylix says it expects another Series C financing round to be completed in 60 days
You may also be interested in...
P&G Teams With Firm To Turn Microbes Into Functional Ingredient "Factories"
Procter & Gamble and Emeryville, Calif.-based Amyris Inc. have entered into a collaborative agreement to leverage the biotech firm's genetically engineered yeast in the development of personal-care ingredients
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.